TB-500 Dosage Guide
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026
Dosage overview
| Typical dose | 4-8 mg per week (loading), 2-4 mg per week (maintenance) |
| Frequency | Two subcutaneous injections per week (loading phase), then once weekly or biweekly |
| Cycle length | 4-6 weeks loading, then 2-4 weeks maintenance. Some protocols cycle 4-6 weeks on, 2-4 weeks off. |
Dosing notes
Not FDA-approved — all dosing information reflects community-reported protocols and research contexts, not medical prescribing guidance. Loading phase protocols commonly reported: 4-8 mg per week split into two subcutaneous injections for 4-6 weeks. The loading phase is intended to achieve tissue saturation before transitioning to lower maintenance doses. Higher loading doses (6-8 mg/week) are sometimes reported for acute injuries, with lower doses (4 mg/week) for general recovery support. Maintenance phase: 2-4 mg every 1-2 weeks. Duration varies — some protocols continue for 8-12 weeks total, while others cycle on and off. Injection is typically administered subcutaneously in the abdomen, deltoid, or near the site of concern. Some protocols recommend injecting near the area of interest based on the rationale that local concentration may benefit targeted tissue, though systemic distribution occurs regardless of injection site. Reconstitution: TB-500 is typically supplied as lyophilized powder requiring reconstitution with bacteriostatic water. Add water slowly along the vial wall, swirl gently — do not shake. Store reconstituted solution refrigerated at 2-8 degrees C (36-46 degrees F) and use within 3-4 weeks. When stacked with BPC-157 ("Wolverine Stack"), both peptides are administered at their respective standard doses in separate injections — they are not typically mixed in the same syringe.
Important safety information
Dosage ranges listed above are based on available research data and reported protocols. Individual dosing should be determined by a qualified healthcare provider based on your specific health profile, goals, and response to treatment.
- Start at the lowest effective dose and titrate up gradually
- Monitor for side effects, especially during dose increases
- Do not exceed researched dose ranges without medical supervision
- This is a research compound — human dosing guidelines are not FDA-established
Interactive protocol guide
Step-by-step: your dosing schedule with exact syringe units, what supplies to buy, how to mix, and how to inject.
TB-500 Protocol Overview
Goal
Healing
Duration
8 weeks
Route
subcutaneous
Important before you start:
- TB-500 is a research peptide. No FDA approval exists for human use.
- Not recommended for individuals with active cancer or a history of cancer.
- Some users report temporary lightheadedness after injection. Sit or lie down if this occurs.
Your dosing schedule
Based on a 5 mg vial mixed with 2 mL bacteriostatic water (2.50 mg/mL concentration). Using a U-50 insulin syringe.
Draw to here
50 units
on 50-unit syringe
1-4: 2.5 mg
Click a row to update
| When | Dose | Syringe units | Frequency | What to expect |
|---|---|---|---|---|
| 1-4 | 2.5 mg | 50 units | Twice weekly | Loading phase. Space injections 3-4 days apart. |
| 5-8 | 2.5 mg | 50 units | Once weekly | Maintenance phase. Reduce frequency, same dose. |
1-4: 2.5 mg
Loading phase. Space injections 3-4 days apart.
5-8: 2.5 mg
Maintenance phase. Reduce frequency, same dose.
What you need for a 8-week TB-500 protocol
TB-500 vials (5 mg each)
Quantity: 6
Bacteriostatic water (30 mL vial)
Quantity: 1
Insulin syringes (U-50, 29ga)
Quantity: 12+ (one per injection, never reuse)
Alcohol prep pads
Quantity: 24+ (one for vial, one for skin)
Sharps container
Quantity: 1
Quantities based on 8-week protocol using 5 mg vials reconstituted with 2 mL BAC water each.
How to mix your TB-500
Your concentration:
5 mg peptide + 2 mL water = 2.50 mg/mL (2500 mcg/mL)
- 1
Wash your hands
Wash with soap and water for 30 seconds. Dry completely.
- 2
Clean the vial tops
Wipe the rubber stopper on your TB-500 vial AND your bacteriostatic water vial with an alcohol swab. Let air dry for 10 seconds.
- 3
Draw 2 mL of bacteriostatic water
Using an insulin syringe, draw 2 mL (100 units on a U-50 syringe) of bacteriostatic water.
- 4
Inject water into the TB-500 vial
Hold the peptide vial at a 45-degree angle. Point the needle at the WALL of the vial, NOT directly onto the powder. Push the plunger slowly over 10-15 seconds. Let the water run down the inside wall.
- 5
Swirl gently to dissolve
Swirl the vial in a slow circular motion for 30-60 seconds. NEVER shake. If not fully dissolved, let it sit for 2-5 minutes and swirl again.
- 6
Refrigerate immediately
Store reconstituted peptide at 36-46 degrees F (2-8 degrees C). Good for 4-6 weeks refrigerated. Label the vial with the date you mixed it.
Common mistakes that ruin your peptide:
- Shaking the vial (breaks peptide bonds, reduces potency 30-50%)
- Spraying water directly on the powder (damages the peptide)
- Using sterile water instead of bacteriostatic water (no preservative, short shelf life)
- Leaving mixed peptide at room temperature (loses 10-20% potency per day)
How to inject TB-500
Timing: Any time of day, consistent timing preferred
- 1Choose your injection site and rotate each time (at least 1 inch from the last site).
- 2Wipe the injection site with an alcohol prep pad. Let air dry completely.
- 3Draw your dose (check the dosing schedule above for exact syringe units).
- 4Pinch a fold of skin at the injection site.
- 5Insert the needle at a 45-90 degree angle into the pinched skin fold.
- 6Push the plunger slowly and steadily.
- 7Release the skin fold, then withdraw the needle.
- 8Do NOT rub the injection site. Light pressure with a cotton ball is fine if there is any blood.
- 9Dispose of the syringe immediately in your sharps container. Never recap or reuse.
Site rotation tip
Divide your preferred injection area into a mental grid. Move to a new spot each injection. For Abdomen and Thigh and Near injury site injections, alternate between sides (left/right) each time.
Research references
- Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice — Wound Repair and Regeneration (2003) [PubMed]
- Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications — Annals of the New York Academy of Sciences (2010) [PubMed]
- Thymosin beta4 and the anti-fibrotic switch — International Immunopharmacology (2023) [PubMed]
- Thymosin beta4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of human induced-pluripotent stem cell-derived cardiomyocytes in a porcine model of acute myocardial infarction — Theranostics (2021) [PubMed]
- Thymosin beta4 Protects against Cardiac Damage and Subsequent Cardiac Fibrosis in Mice with Myocardial Infarction — Cardiovascular Therapeutics (2022) [PubMed]
- Thymosin Beta-4 Induces Mouse Hair Growth — PLoS One (2015) [PubMed]
- Multiple potential roles of thymosin beta4 in the growth and development of hair follicles — Journal of Cellular and Molecular Medicine (2021) [PubMed]
- Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial — Cornea (2015) [PubMed]
- Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model — Clinical Ophthalmology (2015) [PubMed]
- Thymosin beta4 Suppresses LPS-Induced Murine Lung Fibrosis by Attenuating Oxidative Injury and Alleviating Inflammation — Inflammation (2022) [PubMed]
- Neuroprotective and neurorestorative effects of thymosin beta4 treatment following experimental traumatic brain injury — Annals of the New York Academy of Sciences (2012) [PubMed]
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro — Journal of Chromatography B (2024) [PubMed]
- Thymosin beta4 and Actin: Binding Modes, Biological Functions and Clinical Applications — Current Protein & Peptide Science (2023) [PubMed]
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.